Please login to the form below

Not currently logged in
Email:
Password:

Eisai launches epilepsy drug Zebinix in Sweden

Once-daily treatment will compete with Pfizer's Lyrica and UCB’s Vimpat

Eisai has launched its epilepsy drug Zebinix in Sweden after securing full reimbursement from the country's health authorities.

The once-daily drug is approved in Europe as an adjunctive therapy for adults with partial onset seizures, with or without secondary generalisation.

This will put it into competition with more established treatments, like Pfizer's Lyrica (pregabalin) and UCB's Keppra (levetiracetam) and Vimpact (lacosamide) brands.

But with up to a third of epilepsy patients not achieving adequate seizure control after their first anti-epileptic medicine, Eisai will be hoping there's a need for additional treatment options.

Dr Sten Friberg, Nordic medical director for Eisai Europe, said: "Eisai is committed to bringing effective treatments to patients to help improve their quality of life, as displayed by our human health care mission.

“Studies have shown Zebinix to be effective in reducing seizure frequency and provide significant improvements to the patient's quality of life. The launch will provide patients in Sweden with an effective option to manage their seizures." 

Zebinix was approved in Europe in 2009 on the back of phase III trials showing it significantly reduced seizure frequency compared to placebo, while long-term safety and continuation of its effect was demonstrated in one-year open-label extensions of these studies.

Zebinix is one of three drugs Eisai markets in Europe, with the others including Zonegram (zonisamide), another epilepsy treatment.

Zebinix has had a rolling launch across the region, most recently entering the French market. The company also has another drug in the area, perampanel, which has been filed for European approval.

24th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics